Albany, NY -- (SBWIRE) -- 09/21/2017 -- The global anxiety disorders and depression treatment market will log a 1.25% CAGR to go from its 2013 valuation of US$22.5 bn down to US$18.2 bn by 2020.

The report, however, notes that the market for anxiety disorders and depression treatment will be restricted to a great degree by leading drugs in the market on the brink of facing a patent expiration. This is compounded by a relatively dry pipeline of anxiety disorder and depression treatment drugs. The report further notes that drug-resistant mental disorders could pose an impediment to the growth of the global anxiety disorders and depression treatment market.

Data released by the World Health Organization in October 2015 states that over 350 million people across all ages suffer from depression. Given the possibility of acute depression leading to suicide, healthcare agencies are taking measures to tackle the burden using effective drugs and therapies. This will be a high-impact driver for the global anxiety disorders and depression treatment market, says TMR.

TMR analysts recommend players in the market to focus on enhancing and fine-tuning distribution networks in emerging economies and developing herbal therapies to treat depression and anxiety disorders. Countries such as Brazil, China, India, Singapore, Dubai, Mexico, and South Africa have remunerative potential for generic pharmaceuticals, the report states.

Request to view Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1199

For an in-depth analysis, the report segments the global anxiety disorders and depression treatment market on the basis of drug class, pipeline analysis, and geography. Based on drug class, the market is segmented into selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), atypical antipsychotics, tetracyclic antidepressants (TeCAs), beta-blockers, benzodiazepines, and monoamine oxidase inhibitors (MAOIs). Although SNRIs comprised the leading segment in the market as of 2013 with a share of over 30%, their hold on the market is expected to loosen in the coming years.

Likewise, on the basis of pipeline, the market is segmented into Brexpiprazole (OPC-34712), ALKS-5461, and Brintellix (Vortioxetine - Lu AA21004).

Request to Download TOC of the Report: http://www.transparencymarketresearch.com/report-toc/1199

The report studies the following regional markets for anxiety disorders and depression treatment: North America, Asia Pacific, Europe, and Rest of the World. Of these, North America was the leading regional market for anxiety disorders and depression treatment given the high prevalence of depression and anxiety disorders here. However, the report describes this market as nearing saturation – a trend that will only change with the launch of novel drugs for newer symptoms. The growth of the anxiety disorders and depression treatment market in Asia Pacific will be moderate, driven mostly by countries such as Australia, China, and Japan.

Global Anxiety Disorders and Depression Treatment Market Market Report is available @ US$ 5795: http://www.transparencymarketresearch.com/checkout.php?rep_id=1199

About Transparency Market Research
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact us:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/